new studies show continued benefit of satralizumab to treat nmosd
Published 4 years ago • 107 plays • Length 3:39Download video MP4
Download video MP3
Similar videos
-
1:20
new four year data shows satralizumab sustains efficacy and safety in treating nmosd
-
1:27
sakura: long-term safety and efficacy of satralizumab for nmosd
-
20:19
nmosd multidisciplinary approach webinar, 25 june 2021 - dr. suzan ibrahim noori
-
2:54
fda approves satralizumab for neuromyelitis optica spectrum disorder
-
2:00
inebilizumab: proposed mechanism of action for treating nmosd
-
1:39
recent progress and future needs in nmosd treatment
-
1:28
how horizon plans to expand nmosd research
-
4:56
eculizumab: a review in neuromyelitis optica spectrum disorder
-
![nmosd patients often frustrated by delayed diagnosis and misdiagnosis ]](https://i.ytimg.com/vi/C9_vTAcIyyw/mqdefault.jpg)
1:33
nmosd patients often frustrated by delayed diagnosis and misdiagnosis ]
-
3:00
unmet needs in the diagnostics and treatment of nmosd
-
48:53
latest developments in neuromyelitis optica spectrum disorder
-
59:40
2023 nmosd together | live q&a session
-
33:12
2018 rnds — neuromyelitis optica spectrum disorder and optic neuritis
-
21:23
2022 pre-rnds | neuromyelitis optica spectrum disorder (nmosd)
-
3:44
nmosd: pathophysiology and symptoms
-
1:06
neuromyelitis optica spectrum disorder (nmosd)
-
0:47
the importance of treating nmosd early
-
1:21
novel treatment strategies for nmosd
-
20:00
nmosd multidisciplinary approach webinar, 25 june 2021 - dr. luai t. eldweik